Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03190382 · ClinicalTrials.gov registry record · NA
SHOWME-PAD (Peripheral Artery Disease)
A NA study, sponsored by Saint Luke's Health System.
- Completed
- Registry status
- NA
- Development phase
- 72
- Enrollment target
NCT03190382: Completed NA study, sponsored by Saint Luke's Health System.
NCT03190382 is a NA study that has completed, run by Saint Luke's Health System. The registered enrollment target is 72 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03190382, a NA study, has completed, sponsored by Saint Luke's Health System.
- COMPLETED
- Registry status
- NA
- Development phase
- 72 participants
- Enrollment target
Study Summary
The overall goal of SHOWME-PAD is to make the existing evidence-base on treatment outcomes -focusing on health status outcomes that reflect the patients' perspective - more transparently available to patients and providers, such that more informed, evidence-based shared treatment decisions occur. INTEGRITY-PAD has the potential to radically reorganize care delivery to patients with PAD such that more value for the patient and society will be created.
Primary Outcome
The primary outcome of this study will be decisional conflict as measured by the Decisional Conflict Scale.
Interventions
- OTHER Decision Support Tool
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2017-06-24 |
| Est. Completion | 2024-04-01 |
| Phase | NA |
What the finished NCT03190382 record still lists
NCT03190382 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Decision Support Tool is the first listed.
NCT03190382 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03190382 about?
NCT03190382 is a clinical study titled "SHOWME-PAD (Peripheral Artery Disease)". The overall goal of SHOWME-PAD is to make the existing evidence-base on treatment outcomes -focusing on health status outcomes that reflect the patients' perspective - more transparently available to patients and providers, such that more informed, evidence-based shared treatment decisions occur. IN...
What is the current status of trial NCT03190382?
This trial is currently completed. It is a NA study. The enrollment target is 72 participants. The study started on 2017-06-24. Estimated completion is 2024-04-01.
What interventions are being tested in trial NCT03190382?
The interventions under investigation include: Decision Support Tool (OTHER).
Who is sponsoring clinical trial NCT03190382?
This trial is sponsored by Saint Luke's Health System, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03190382's enrollment target sits among peer trials
72 1089th of 2000 higher than 899 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI